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Streptococcus pneumoniae is the main bacterial cause of respiratory infections in
children and the elderly worldwide. Serotype replacement is a frequent phenomenon
after the introduction of conjugated vaccines, with emerging serotypes 22F and 33F
as frequent non-PCV13 serotypes in children and adults in North America and other
countries. Characterization of mechanisms involved in evasion of the host immune
response by these serotypes is of great importance in public health because they
are included in the future conjugated vaccines PCV15 and PCV20. One of the main
strategies of S. pneumoniae to persistently colonize and causes infection is biofilm
formation. In this study, we have evaluated the influence of capsule polysaccharide in
biofilm formation and immune evasion by using clinical isolates from different sources
and isogenic strains with capsules from prevalent serotypes. Since the introduction of
PCV13 in Spain in the year 2010, isolates of serotypes 22F and 33F are rising among
risk populations. The predominant circulating genotypes are ST43322F and ST71733F ,
being CC433 in 22F and CC717 in 33F the main clonal complexes in Spain. The use of
clinical isolates of different origin, demonstrated that pediatric isolates of serotypes 22F
and 33F formed better biofilms than adult isolates and this was statistically significant.
This phenotype was greater in clinical isolates from blood origin compared to those
from cerebrospinal fluid, pleural fluid and otitis. Opsonophagocytosis assays showed
that serotype 22F and 33F were recognized by the PSGL-1 receptor on leukocytes,
although serotype 22F, was more resistant than serotype 33F to phagocytosis killing
and more lethal in a mouse sepsis model. Overall, the emergence of additional PCV15
serotypes, especially 22F, could be associated to an enhanced ability to divert the host
immune response that markedly increased in a biofilm state. Our findings demonstrate
that pediatric isolates of 22F and 33F, that form better biofilm than isolates from adults,
could have an advantage to colonize the nasopharynx of children and therefore, be
important in carriage and subsequent dissemination to the elderly. The increased ability
of serotype 22F to avoid the host immune response, might explain the emergence of
this serotype in the last years.
Keywords: Streptococcus pneumoniae, PCV-pneumococcal conjugate vaccine, biofilms, serotype 22F, serotype
33F, PSGL-1
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INTRODUCTION
Streptococcus pneumoniae, also termed pneumococcus, colonizes
asymptomatically the human nasopharynx although the
bacterium has the capacity to reach the lower respiratory tract
(LRT) producing pneumonia and disseminate producing invasive
pneumococcal disease (IPD) (Bogaert et al., 2004). The burden
of disease caused by this microorganism is of great relevance
because is the major etiologic agent of community acquired
pneumonia, non-epidemic meningitis and a frequent cause of
bacterial sepsis (Bogaert et al., 2004). As a result, this devastating
pathogen is responsible for high morbidity and mortality rates
worldwide affecting mainly the children under the age of 5 years
and adults older than 65 years. Indeed, nearly 2.38 million
deaths are caused by LRT infections, being S. pneumoniae the
major etiologic agent of these alarming rates (GBD 2016 Lower
Respiratory Infections Collaborators, 2018). As a consequence,
LRT infections are the sixth mortality cause for all ages and the
first cause of death among children under 5 years old (GBD 2016
Lower Respiratory Infections Collaborators, 2018). While the use
of available antibiotics is the best option to treat pneumococcal
infections once they are established, the emergence of multidrug
resistant strains can jeopardize the outcome of the infection in
many cases (Aguinagalde et al., 2015; Azarian et al., 2018).
Prophylactic measures based on the administration of
pneumococcal vaccines in children and adults, seems to be the
best strategy to control the development of IPD and pneumonia
and reduce the impact of antimicrobial resistance (Moore et al.,
2015; Atkins et al., 2018; Wahl et al., 2018). In children under
2 years old, there are currently two vaccines available, a 10-
valent conjugate vaccine (PCV10) and a 13-valent conjugate
vaccine (PCV13). The use of PCV10 has decreased the burden
of disease caused by serotypes covered in the vaccine but several
countries using this vaccine have reported the emergence of non-
PCV10 serotypes such as 19A after its introduction (Savulescu
et al., 2017; Cassiolato et al., 2018; Rinta-Kokko et al., 2018).
PCV13 has shown to be effective in children who were the main
target for this vaccine but also has shown herd effects for the
elderly population (Mackenzie et al., 2016). In adults, the 23-
valent polysaccharide vaccine (PPV23) can be used to prevent
IPD although its effectiveness against pneumonia is controversial
(Huss et al., 2009; Andrews et al., 2012; Russell et al., 2015;
Tin Tin Htar et al., 2017). The use of PCV13 has been shown
to be effective avoiding IPD and pneumonia in the elderly
population (Bonten et al., 2015; McLaughlin et al., 2018). The
main limitation of these vaccines is that serotype replacement
is a frequent phenomenon that occurs after the massive use of
these vaccines based on capsular polysaccharides due to the wide
antigenic variability of this bacterium with up to 99 serotypes
described so far and emergence of virulent clones with vaccine-
escape capsule (Brueggemann et al., 2007; Domenech et al.,
2018). To target the emergence of non-vaccine types producing
pneumococcal infection, a 15-valent conjugate vaccine (PCV15)
including serotypes covered by PCV13 plus serotypes 22F and
33F is in clinical phase III with the advantage of inducing a
higher title of antibodies against serotype 3 (Greenberg et al.,
2018; Stacey et al., 2019). In addition, a 20-valent conjugate
vaccine (PPV20) that contains serotypes in PCV15 plus serotypes
8, 10A, 12F, 11A, and 15B is also in clinical trials studies
(Thompson et al., 2019).
The emergence of many of these serotypes in certain countries
after the use of current PCVs is one of the main reasons for
including these additional serotypes in newer conjugate vaccines.
In United States, serotypes 22F and 33F were the main cause of
IPD among non-PCV13 in children under 5 years old and adults
≥65 years (Moore et al., 2015). In Europe, several countries have
shown the rise of non-PCV13 serotypes in children and adults
including serotypes covered by PCV15 and PCV20 (Aguinagalde
et al., 2015; Savulescu et al., 2017; Ladhani et al., 2018).
Nevertheless, one aspect that is poorly investigated before the
introduction of new conjugate vaccines is the pathogenic capacity
of these additional serotypes.
It is been known that biofilm formation in S. pneumoniae
provides the bacterium an advantage in terms of virulence
because it increases the resistance to antimicrobial drugs and
enhances the ability to avoid the host immune response
(Donlan and Costerton, 2002; Domenech et al., 2013). For
instance, serotypes 11A and 35B, which are serotypes frequently
associated to multidrug resistance, are good biofilm formers
(Domenech et al., 2015). Biofilm formation is a critical aspect
from the pathogenesis perspective because S. pneumoniae has
been reported to form biofilms in the upper respiratory tract
(Wu et al., 2017; Iverson et al., 2019; Silva and Sillankorva,
2019) and nasopharyngeal colonization is the initial step in
this process and the prerequisite for developing IPD (Bogaert
et al., 2004). Interestingly, active infection is also associated
to pneumococcal biofilms in meningitis by binding to brain
microvascular endothelial cells and in persistent respiratory
infection affecting patients with cystic fibrosis or chronic
obstructive pulmonary disease (COPD) (Orihuela et al., 2009;
Vidal et al., 2013; Vandevelde et al., 2014; Dennis et al., 2018). In
the biofilm state, pneumococcal cells express the PspC protein in
a higher extent, and this protein is the bacterial ligand associated
to the recruitment of factor H and therefore to the cleavage of the
C3 complement system protein deposited on the bacterial surface
(Domenech et al., 2013). This is interesting in terms of virulence
because when pneumococcal cells are released from the biofilm
producing dissemination to the LRT, the bloodstream or crossing
the blood brain barrier producing meningitis, these colonies
express higher levels of the virulence factor PspC increasing the
potential for IPD (Yuste et al., 2010).
In contrast to Neisseria meningitidis, bactericidal activity by
the membrane attack complex of the complement system plays
a minor role against S. pneumoniae and killing by professional
phagocytes in the presence or not of specific antibodies, is the
most efficacy mechanism to fight the pneumococcal infection
(Standish and Weiser, 2009). For this reason opsonophagocytosis
killing assays (OPKA) are the best parameter to measure the
functional opsonic activity of antibodies to S. pneumoniae
when a new vaccine is tested (Greenberg et al., 2018; Stacey
et al., 2019; Thompson et al., 2019). Hence, investigating
these aspects will contribute to increase the knowledge about
the potential of non-vaccine serotypes to produce infection
in the host. Differences in the recognition of pneumococcal
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serotypes by specific components of the host immune response
may explain the prevalence of certain serotypes causing IPD
(Hyams et al., 2011). In this sense, the human P-selectin
glycoprotein ligand 1 is a novel receptor for S. pneumoniae that
contributes to protection against IPD by controlling the severity
of the infection (Ramos-Sevillano et al., 2016). This receptor is
present on leukocytes that recognizes the pneumococcal capsular
polysaccharide and the main autolytic enzyme of the bacterium
(the amidase LytA) increasing the phagocytosis process (Ramos-
Sevillano et al., 2016). Differences in the interaction of different
pneumococcal capsules with PSGL-1 might explain the higher
burden of disease caused by certain serotypes of S. pneumoniae
(Ramos-Sevillano et al., 2016).
In this study, we have evaluated the impact of current
vaccine strategies in the epidemiology of serotypes 22F and 33F
during the period 2009–2018 including the circulating genotypes
that cause IPD among these serotypes. In addition, we have
characterized the ability of serotypes 22F and 33F to form biofilms
and their capacity to avoid the phagocytosis process and produce
infection because they are important aspects that are missing
for these additional serotypes covered in the new PCV15. For
comparison purposes, we also included pneumococcal serotypes
that are prevalent in IPD and/or because they are associated to
multidrug resistance.
MATERIALS AND METHODS
Strains, Media and Genetic
Transformation
The pneumococcal strains of the different serotypes used in this
study are listed in Table 1. The Spanish Pneumococcal Reference
Lab (SPRL) receives the IPD cases from hospitals located at all
the Spanish regions through a passive surveillance system with
minimal required information accompanying isolates (hospital
and city, sample, age of the patient and date of isolation).
The SPRL notifies annually to the European Center for Disease
Control (ECDC) all the IPD cases received following a passive
surveillance system that cover 80% of the national level according
to estimates by the National Center for Epidemiology reported
to ECDC (ECDC, 2018). Unfortunately, vaccine coverage data
is not available and that is the reason that effectiveness of the
different vaccines cannot be included in this study. Initially,
PCV7 coverage based on vaccine sales was low, but its use
increased from 2002 onward with reported vaccine coverage
below 50% before 2006 and missing data on PCV coverage at
national level in further years (Fenoll et al., 2015).
All pneumococcal strains were grown in C medium
supplemented (C+Y medium) or in Mueller Hinton agar
supplemented with 5% defibrinated sheep blood (Becton
Dickinson GmbH; Heidelberg, Germany). Bacterial growth was
monitored by measuring the absorbance at 550 nm (A550).
S. pneumoniae was transformed with chromosomal DNA by
treating pre-competent cells with 100 ng/ml of synthetic
competence-stimulating pheromone 1 at 37◦C for 10 min to
induce competence, followed by incubation at 30◦C during DNA
uptake. Encapsulated transformants of strain M11 were enriched
by successive transfers of the transformed culture to C medium
containing 0.08% bovine serum albumin, and supplemented with
0.5 µl/ml of anti-R antiserum before plating (Mollerach et al.,
1998; Domenech et al., 2015). Anti-R (antisomatic) antiserum
contains group-specific agglutinins, which, at the proper dilution,
agglutinate only non-encapsulated pneumococci. In this study,
we have used isogenic mutants in CPS in order to reduce the
influence of genetic variability within the strains. To confirm the
absence of mutations in other parts of the genome, we used two
independent transformants of each serotype with not differences
in the phenotype. Based on this, only one transformed strain of
each serotype was further studied for the rest of the experiments.
The selection of pneumococcal isolates for immune response
characterization and biofilm formation was randomly chosen.
We selected five clinical isolates from each source (20 clinical
isolates of serotype 22F and another 20 clinical isolates of serotype
33F) from different geographical locations in Spain (Table 1).
Moreover, we did biofilm formation trials in parallel with clinical
strains of the serotypes studied as control.
S. pneumoniae Typification
In addition to strains showed in Table 1, we included the
clinical isolates of serotypes 22F and 33F received at the
Spanish Pneumococcal Reference Laboratory (SPRL) since 2009
to analyze the evolution of IPD caused by both serotypes
in Spain. We considered IPD clinical isolates those isolated
from sterile sites. Serotyping was performed by Quellung
reaction, dot blot assay (Fenoll et al., 2015) using specific
antisera from the Statens Serum Institut (Copenhagen, Denmark)
and/or by molecular capsular sequence typing methodology
(Elberse et al., 2011).
Multilocus sequence typing (MLST) was determined with the
tools provided by the MLST website1. Data were analyzed using
Lasergene R©SeqMan Pro (DNAStar, Madison,WI, United States).
Sequence types (STs) were identified based on the allelic profiles
of seven housekeeping genes (aroE, ddl, gdh, gki, recP, spi, and
xpt). We used the eBURST tool to determine the clonal complex
(CC) (Feil et al., 2004). STs were considered from the same CC if
they demonstrated ≥5 MLST allele numbers in common.
Biofilm Formation Assay
Biofilm formation assays were performed following the
methodology previously described (Domenech et al., 2015)
and it was determined by the ability of cells to adhere to the
walls and base of 96-well, flat-bottomed polystyrene microtiter
dishes (Falcon 353072, Corning Incorporated, New York, NY,
United States). Unless stated otherwise, cells were grown in C+Y
medium to an A550 of ≈0.5–0.6, sedimented by centrifugation,
resuspended in an equal volume of the indicated pre-warmed
medium, diluted 1/100, and then dispensed 200 µl per well. After
5 h of incubation at 34◦C, the A595 was determined using Tecan
Infinite F200 (Tecan Group Ltd., Switzerland). The biofilm
formed was stained with 0.2% crystal violet (Sigma-Aldrich)
and rinsed three times with distilled water to remove non-
adherent bacteria. Biofilm formation was quantified solubilizing
1http://pubmlst.org/spneumoniae
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TABLE 1 | Strains of S. pneumoniae used in this studya.
Strain Description/serotype (source)b ST/CCc References/sourced
M11 Non-encapsulated strain derived from R6 (Hex−, lytA+) Domenech et al., 2014
YNM2 M11 transformant with DNA from strain 1734/19; serotype 8 This study
1734/19 8(blood) SPRL
YNM3 M11 transformant with DNA from strain 1732/19; serotype 11A This study
1732/19 11A(blood) SPRL
YNM4 M11 transformant with DNA from strain 1228/19; serotype 19A This study
1228/19 19A(blood) SPRL
P007 M11 transformant with DNA from strain 406; serotype 3 Domenech et al., 2009
P224 M11 transformant with DNA from strain 3017/13; serotype 24F Domenech et al., 2014
P244 M11 transformant with DNA from strain 3014/13; serotype 22F Domenech et al., 2015
1407/18 22F(blood/pediatric) ST3134/CC1439 SPRL
1000/18 22F(blood/adult) ST13692/CC698 SPRL
1155/18 22F(CSF/pediatric) ST433/CC433 SPRL
523/18 22F(CSF/adult) ST13692/CC698 SPRL
223/11 22F(PF/pediatric) ST433/CC433 SPRL
1285/18 22F(PF/adult) ST698/CC698 SPRL
2780/17 22F(Otic/adult) ST13692/CC698 SPRL
100/08 22F(Otic/pediatric) ST433/CC433 SPRL
1766/18 22F(blood/pediatric) ST3134/CC1439 SPRL
2597/17 22F(blood/pediatric) ST433/CC433 SPRL
194/17 22F(blood/pediatric) ST433/CC433 SPRL
2153/17 22F(blood/pediatric) ST433/CC433 SPRL
212/18 22F(blood/adult) ST698/CC698 SPRL
250/18 22F(blood/adult) ST433/CC433 SPRL
306/18 22F(blood/adult) ST433/CC433 SPRL
613/18 22F(blood/adult) ST7314/CC433 SPRL
P017 M11 transformant with DNA from strain SSISP33F/1; serotype 33F Domenech et al., 2015
1833/18 33F(blood/pediatric) ST717/CC717 SPRL
1950/18 33F(blood/adult) ST13320/CC717 SPRL
1088/16 33F(CSF/pediatric) ST717/CC717 SPRL
934/19 33F(CSF/adult) ST717/CC717 SPRL
800/18 33F(PF/pediatric) ST717/CC717 SPRL
363/18 33F(PF/adult) ST717/CC717 SPRL
782/15 33F(Otic/pediatric) ST1012/CC1012 SPRL
1945/15 33F(Otic/pediatric) ST717/CC717 SPRL
644/18 33F(blood/pediatric) ST717/CC717 SPRL
1018/18 33F(blood/pediatric) ST717/CC717 SPRL
1992/18 33F(blood/pediatric) ST4668/CC717 SPRL
2316/17 33F(blood/pediatric) ST13320/CC717 SPRL
1897/18 33F(blood/adult) ST717/CC717 SPRL
2027/18 33F(blood/adult) ST717/CC717 SPRL
627/18 33F(blood/adult) ST717/CC717 SPRL
840/18 33F(blood/adult) ST717/CC717 SPRL
aStrains are organized by serotype. bCSF, cerebrospinal fluid; PF, pleural fluid. cST, sequence type; CC, clonal complex. dSPRL, Spanish Pneumococcal
Reference Laboratory.
the biofilm in 95% ethanol (200 µl per well) and measuring
the A595.
Phagocytosis of S. pneumoniae Biofilms
and Planktonic Cultures
Experiments investigating human neutrophil phagocytosis were
performed by OPKA using HL-60 cells (CCL-240; ATCC)
differentiated to granulocytes (Domenech et al., 2013). The
presence of complement receptors on HL-60 granulocytes has
been previously documented and therefore expression of CD11b
(iC3b receptor and CR3 α-chain), a marker of granulocytic
differentiation, was measured prior to phagocytic assays to
confirm the presence of the receptor (Ramos-Sevillano et al.,
2016). After the incubation process at 34◦C (previously described
in biofilm formation), bacterial cultures growing as biofilms
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in microtiter plates or the planktonic cultures in tubes were
washed with fresh C medium and resuspended in Hank’s
buffered salt solution (HBSS) in the presence of calcium and
magnesium ions. Biofilm disaggregation was performed by gently
pipetting and slow vortexing before the opsonization process
to avoid possible bias by morphological differences between the
two growing stages. The number of biofilm-forming CFU was
determined by viable counts of bacteria and a similar number
of planktonic cells were used in each phagocytosis assay. OPKA
were performed using 105 HL-60 cells and 2.5 × 102 CFU of
S. pneumoniae strains (MOI of 400 HL-60:1 S. pneumoniae)
that were previously opsonized for 1 h with 1/20 of rabbit
serum in the case of planktonic cultures, and 20 min with
1/5 of rabbit serum in the case of biofilm cultures. First,
the corresponding bacterial suspensions (10 µl) were added
to microtiter round bottom polystyrene plates (Nunclon Delta
Surface; Themo Fisher Scientific) containing 10 µl of rabbit
serum diluted 1/20 or 1/5 in phosphate-buffered saline (PBS,
pH 7.0) previously described (Domenech et al., 2013). After
incubation at 37◦C with shaking (150 rpm) to allow opsonization
by the different serum components, HL-60 cells were added and
the plate was incubated at 37◦C with shaking (150 rpm) for
45 min. The mixture was plated on blood agar plates for bacterial
counts determination and results were expressed as bacterial
killing. Blood agar plates were incubated at 37◦C with 5% CO2
during 24 h for determinate viable cells.
Phagocytosis Mediated by PSGL-1
Receptor
To analyze the function of the PSGL-1 receptor in recognizing
the CPS of the new emerging serotypes 22F and 33F, and isogenic
strains expressing different CPS, we followed the methodology
previously described (Ramos-Sevillano et al., 2016). To block
PSGL-1, HL-60 cells were incubated for 1 h at 37◦C with
25 µg/ml of the KPL-1 antibody (mouse antihuman PSGL-1;
MBL) or IgG isotype control (mouse anti-human IgG; Novus
Biologicals). The phagocytosis killing assays were performed in
the absence of rabbit serum using a proportion of 105 HL-
60 cells with the PSGL-1 receptor either active or blocked
and 2.5 × 102 CFU of S. pneumoniae. Then, as mentioned
above, we plated on blood agar plates serial dilutions of culture
for bacterial counts determination. Results were expressed
normalizing CFU/ml to percentage of phagocytosis using the IgG
isotype control as the 100%.
Mouse Model of S. pneumoniae Sepsis
Experimental procedures involving mice were performed at
Instituto de Salud Carlos III (ISCIII) conforming to the
Spanish government legislation (RD 53/2013, ECC/566/2015)
and European Community regulations (2010/63/EU). C57BL/6
male mice (8–12 weeks old) weighing about 20 g were bred
by the ISCIII animal facility. Animal procedures followed the
guidelines of the Bioethical and Animal Welfare Committee of
ISCIII that reviewed and approved protocols (CBA PA 52-2011-
v2 and PROEX 218/15). Studies investigating pneumococcal
sepsis were performed using groups of five mice and infected
as previously described (Ramos-Sevillano et al., 2016). Briefly,
for sepsis, mice were challenged with 2 × 107 CFU/mouse
for P244, P017, 1407/18, 1000/18, 1833/18, and 1950/18 strains
(Table 1) (in a volume of 200 µl) by the intraperitoneal route.
Bacterial levels in blood, from the tail vein, were determined from
every infected mouse at 24 h. The lower limit of detection was
102 CFU/ml. Results were expressed as Log10 CFU/ml of bacteria
recovered from the blood and survival curves were determined
after 7 days of follow up.
Statistical Analysis
Data represent results obtained from repeated independent
experiments, each one conducted as a triplicate, representing
at least three replicates. Statistical analysis was performed by
using two-tailed Student’s t-test. The log-rank (Mantel-Cox) test
was used for survival curves. Incidence rates were calculated
considering the number of cases divided by the population using
data provided by the Spanish National Institute of Statistics.
Serotype trends were obtained by comparing the rates of the
current situation (2017–2018) vs. the rates of different periods
by calculating relative risks (IRR) with 95% confidence intervals
through Poisson regression models. We included the pre-PCV13
period (2009), the early PCV13 effect (2010–2012) and the middle
PCV13 period (2013–2016) when this vaccine was included in the
pediatric calendar at national level at the end of 2016. Statistical
analyses for epidemiological data were analyzed using Stata v.14.
GraphPad InStat version 8.0 (GraphPad Software, San Diego,
CA) was used for the rest of analysis. Differences were considered
statistically significant with ∗P < 0.05 and highly significant with
∗∗P < 0.01 and ∗∗∗P < 0.001.
RESULTS
Evolution of Invasive Pneumococcal
Disease by Serotypes 22F and 33F in
Spain
The epidemiological situation of IPD cases by clinical isolates
of serotypes 22F and 33F was investigated during the last
10 years including 2009 which is the pre-PCV13 year and
2018 which is the last year when epidemiological data is fully
registered in Spain.
The data contain cases, proportion among all IPD cases and
incidences by these two serotypes. Incidences were calculated
considering the number of cases divided by the population
using data provided by the Spanish National Institute of
Statistics. Incidence rate ratios with 95% confidence intervals
were estimated to compare the current situation (2017–2018)
vs. different periods including the pre-PCV13 period (2009), the
early PCV13 effect (2010–2012) and the middle PCV13 period
(2013–2016) when this vaccine was included in the pediatric
calendar at national level at the end of 2016.
In children, IPD cases by serotype 22F showed a similar trend
until 2016 (6 cases in 2009 vs. 8 cases in 2016) which is the year
when PCV13 was introduced at the national pediatric vaccination
calendar (Figure 1A). However, since 2016 we observed a
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FIGURE 1 | Trends in IPD incidence due to serotypes 22F and 33F producing IPD episodes in the pediatric population during the period 2009–2018 in Spain.
(A) Number of IPD cases. (B) Incidence of IPD cases. Green line with dots is the evolution of serotype 22F whereas red line with squares is the evolution of
serotype 33F.
continuous rise with 13 cases in 2017 and 16 cases in 2018 or 29
cases in the last epidemiological period 2017–2018 showing the
emerging of this serotype in children (Figure 1). The proportion
of IPD cases by serotype 22F was 1.08% in 2009 and 6.23% in
2018 confirming that this serotype is rising and increasing its
proportion over total serotypes in the pediatric population. IPD
cases by serotype 33F in children show a moderate rise during
the last 10 years when comparing 2009 vs. 2018 increasing from
6 cases in 2009 to 8 cases in 2018 and 13 cases for the last
2 years (Figure 1). Incidence rate ratios (IRR) for serotype 22F
demonstrate an increasing trend (IRR 2.38; 95% CI 0.99–5.74 for
the period 2017–2018 vs. 2009, IRR 1.82; 95% CI 1.06–3.12 for
2017–2018 vs. 2010–2012, and IRR 1.88; 95% CI 1.13–3.11 for
2017–2018 vs. 2013–2016 (Table 2). However, for serotype 33F
the situation is relatively stable in the last 10 years (IRR 1.07;
95% CI 0.41–2.81 for the period 2017–2018 vs. 2009, IRR 0.98;
95% CI 0.49–1.97 for 2017–2018 vs. 2010–2012, IRR 0.90; 95%
CI 0.47–1.73 for 2017–2018 vs. 2013–2016 (Table 2). Overall, our
results suggest that serotype 22F is more prevalent in Spanish
children than serotype 33F with a more pronounced effect in the
last 2 years concurring with the introduction of PCV13 in the
national immunization pediatric calendar.
In adults of all ages, serotypes 22F and 33F show an increase
of 52% (64 cases vs. 132 cases) and 48% (26 cases vs. 50 cases),
respectively, when the pre-PCV13 period (year 2009) is compared
to the last year 2018 (Figure 2). Hence, incidence by serotype 22F
increased from 0.17 cases per 100000 in 2009 to 0.24 cases per
100000 in 2013–2016 and 0.32 cases per 100000 in 2017–2018.
Incidence rate ratios show that serotype 22F rapidly increase
after PCV13 was introduced in Spain with a constant increasing
trend until 2018 (IRR 1.95; 95% CI 1.48–2.56 for 2017–2018 vs.
2009, IRR 1.39; 95% CI 1.17–1.65 for 2017–2018 vs. 2010–2012
and IRR 1.37; 95% CI 1.16–1.61 for 2017–2018 vs. 2013–2016)
(Table 2). For serotype 33F, a similar pattern was observed after
the introduction of PCV13 (IRR 1.70; 95% CI 1.10–2.64 for 2017–
2018 vs. 2009, IRR 1.86; 95% CI 1.36–2.54 for 2017–2018 vs.
2010–2012 and IRR 1.41; 95% CI 1.15–1.74 for 2017–2018 vs.
2013–2016) (Table 2). In adults 18–64 years old, only serotype
22F increased since the introduction of PCV13 from 0.09 cases
per 100000 in 2009 to 0.16 cases per 100000 in 2017–2018 (IRR
1.82; 95% CI 1.18–2.78). For adults≥65 years, an increased in the
incidence of both serotypes has been observed comparing 2009
and 2017–2018 (IRR 1.83; 95% CI 1.28–2.62 for serotype 22F and
IRR 2.00; 95% CI 1.1–3.64 for serotype 33F). Hence, these data
demonstrate that both serotypes 22F and 33F are emerging in
adults being serotype 22F one of the most prevalent in 2018 for
Spanish adults≥65 years (3rd cause of IPD) whereas serotype 33F
is the 16th cause of IPD in this age group (unpublished data from
our laboratory).
Genetic Analysis of Circulating Clones
Among Clinical Isolates of Serotypes 22F
and 33F
Genetic diversity of clinical isolates of serotypes 22F and 33F
producing IPD in Spain was assessed by MLST. We chose the
year 2018 to know the circulating genotypes of 22F and 33F
because is an early time-point after the introduction of PCV13
in the pediatric calendar by the end of 2016 and even in the adult
calendar of certain Spanish regions. In Spain, PCV7 was mainly
used in private market and low selection pressure is expected.
Isolates of serotype 22F contained five different sequence types
being ST433 the most frequent with up to 58% of the isolates
belonging to this sequence type (Table 3). These genotypes were
grouped into three different clonal complexes although CC433
was associated to 71% of the isolates of serotype 22F (Table 3).
Isolates of serotype 33F also had five different genotypes being
ST717 the most popular containing 71% of the strains, followed
by ST 13320 with 18% of the isolates (Table 3). In contrast
to serotype 22F, isolates of serotype 33F showed a less variable
diversity in terms of clonal complexes with CC717 being the
most frequent with up to 93% of the strains (Table 3). Overall,
clinical isolates of serotypes 22F and 33F that are producing the
majority of the IPD cases in the Spanish population seem to be
very conserved with ST433 and ST717 being the most frequent
genotypes among 22F and 33F, respectively (Table 3).
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Pneumococcal Biofilms of Serotypes 22F
y 33F From Different Sources
Figure 3 shows the biofilm formation capacity of clinical isolates
of serotypes 22F (Figure 3A) and 33F (Figure 3B) from four
different sources: blood, cerebrospinal fluid (CSF), pleural fluid
(PF) and otic (Table 1). We also wanted to detect if there
were differences in biofilm formation when the clinical isolate
was either pediatric or adult (except for an adult clinical
isolate of serotype 33F from otitis, which could not be tested).
As biofilm formation controls, we used the non-encapsulated
S. pneumoniae M11 strain, and isogenic mutants containing the
genetic background of strain M11 and the capsules of serotypes
22F (P244) or 33F (P017). One clinical isolate of each serotype
and origin were analyzed in detail. Although pneumococci
of every serotype tested produced less biofilm than the non-
encapsulated strain M11, significant differences were noted in the
biofilm formation capacity of several pairs of clinical strains of
the same serotype. The pediatric isolates formed greater biofilm
than adult isolates, this difference being statistically significant
in the case of clinical isolates from blood and otitis of serotype
22F (Figure 3A) and from blood and CSF of serotype 33F
(Figure 3B). We also observed that there are clinical isolates
of serotypes 22F or 33F that formed more or less biofilm
than the isogenic transformant P244 or P017 (Figure 3). These
results confirm previous observations indicating that the genetic
background, and not only the CPS, modulates pneumococcal
attachment to the artificial substrate (Moscoso et al., 2006;
Domenech et al., 2014, 2015).
Comparing globally all the results of biofilm formation of
pediatric isolates with those from adults (Figure 4A), biofilm
formation was greater in clinical isolates of pediatric origin being
statistically significant (∗∗∗P < 0.001). In Figure 3, we observed
that, clinical pediatric isolates from blood were the best biofilm
formers than isolates from the others sources (CSF, PF, otic)
regardless of the serotype analyzed. In addition, if we compare a
higher number of pediatric isolates from blood with adult isolates
of each serotype (Figure 4B), we observed again, that pediatric
blood isolates formed better biofilms than adult isolates and this
phenotype was serotype-independent.
Comparison of ST and clonal complexes with biofilm
formation based on the clinical origin of the isolates does not
allow establishing a possible relationship between the genotype of
the strain (Table 1 and Figures 3, 4), biofilm formation capacity
and the origin of the sample.
Opsonophagocytosis of Different
Serotypes With the Same Genetic
Background Growing as Planktonic or
Biofilms Cultures
To explore the potential of different serotypes to avoid the
opsonophagocytosis process by human neutrophils which could
explain differences in the burden of disease at the epidemiological
level, isogenic transformants of M11 strain were used (Figure 5).
For this study, PCV13 serotypes such as 3 and 19A and
non-PCV13/PCV15 serotypes such as 8, 11A and 24F were
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FIGURE 2 | Trends in IPD incidence due to serotypes 22F and 33F producing IPD episodes in adults during the period 2009–2018 in Spain. (A) Number of IPD cases
of serotype 22F. (B) Incidence of IPD cases of serotype 22F. (C) Number of IPD cases of serotype 33F. (D) Incidence of IPD cases of serotype 33F. Black line with
triangles is the evolution in adults of all ages. Green line with dots is the evolution in adults 18–64 years. Red line with squares is the evolution in adults ≥65 years.
TABLE 3 | Genotype and clonal complex distribution of S. pneumoniae 22F and
33F clinical isolates from the year 2018.
Serotype/Clonal
complex (CC)



















included based in their high prevalence rates of these serotypes
causing IPD in Europe (Fenoll et al., 2015). Serotype 11A is
an emerging multidrug resistant phenotype and a good biofilm
former (Aguinagalde et al., 2015; Domenech et al., 2015), whereas
serotypes 22F and 33F contained in PCV15 were included for
comparison purposes.
The use of the M11 strain for constructing all the isogenic
transformants, being the CPS as the only difference among the
strains, is the best strategy to assess variations in the phagocytosis
process mediated by the CPS and not by differences related to
the genetic background of the strains. OPKA was measured using
bacteria growing as planktonic culture or biofilms.
In planktonic cultures, the analysis of the two most frequent
PCV13 serotypes, confirmed that isolate with CPS of type 3 was
more resistant to the phagocytosis than the isolate expressing
serotype 19A proving than the CPS of serotype 3 conferred
more resistance to the phagocytosis than the capsule of type 19A
(∗∗∗P < 0.001) (Figure 5A). The two new additional serotypes
included in PCV15 showed a different pattern of recognition
by the phagocytic cells. The capsule 22F was more resistant to
the phagocytosis process than the capsule 33F (∗∗∗P < 0.001)
(Figure 5A). These results may explain why serotype 22F is more
frequent causing IPD in children and adults than serotype 33F
(Figures 1, 2). Strains expressing the CPS of types 8 and 11A
had the most resistant phenotype whereas the strain with the CPS
of type 24F was phagocytosed as the same level than the CPS of
19A (Figure 5A).
In biofilm cultures, the strain expressing serotype 3 was
more resistant to the phagocytosis process than serotype 19A
upholding the marked resistant level of serotype 3 to the
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FIGURE 3 | Biofilm formation of pediatric and adult clinical isolates from four
different origins. (A) Represents clinical isolates of serotype 22F (B).
Represents clinical isolates of serotypes 33F. M11, non-encapsulated strain;
P244, 22F isogenic transformant; P017, 33F isogenic transformant; P,
pediatric isolates; A, adult isolates; CSF, cerebrospinal fluid; PF, pleural fluid.
Black bars represent growth and pattern or pattern-less bars represent biofilm
formation. All data were normalized to the A595 CV blanks. Error bars
represent standard deviations, and asterisks mark results that are statistically
significant (two-tailed Student’s t-test: *P < 0.05; **P < 0.01; ***P < 0.001).
phagocytosis (Figure 5B, ∗∗∗P < 0.001). Among the two
additional serotypes included in PCV15, the strain expressing
the CPS of serotype 22F was more resistant to phagocytosis than
the strain of serotype 33F suggesting that serotype 22F may have
an enhanced ability to colonize and produce persistent infection
associated to biofilms than serotype 33F (Figure 5B). The strain
with the CPS of type 8 had a similar pattern of phagocytosis
evasion than the strain expressing the serotype 19A (Figure 5B).
Finally, serotypes 11A and 24F avoided very efficiently the
phagocytosis in comparison to the control strain (Figure 5B).
Evasion of Phagocytosis by Clinical
Isolates of Serotypes 22F and 33F From
Children and Adults
In this study, we analyzed the recognition of pneumococcal
serotypes 22F and 33F by phagocytic cells using clinical isolates
from blood obtained from children and adults with IPD and
grown as planktonic or biofilms (Figure 6). For serotype 22F,
no differences were found between pediatric or adult isolates
suggesting that this serotype may affect both target populations at
a similar level and therefore, it may be useful to vaccinate children
and adults against serotype 22F (Figure 6). In the case of serotype
33F, a higher resistance level to phagocytosis was observed in
the pediatric isolate grown as planktonic culture (Figure 6A)
whereas no differences were observed between isolates as biofilms
(Figure 6B), suggesting that children may be more susceptible to
IPD by this serotype.
Role of PSGL-1 Receptor in the
Phagocytosis of Prevalent
Pneumococcal Serotypes Included or
Not in Conjugate Vaccines
The interaction of pneumococcal serotypes with the PSGL-1
receptor was studied in the absence of serum to avoid any
effect on phagocytosis by serum-mediated receptors such as
complement receptors. In the absence of pneumococcal capsule
(control strain M11), we did not observe any difference on
phagocytosis independently of the functionality of the PSGL-1
receptor, confirming that the capsule is necessary for the PSGL-
1 mediated phagocytosis (Figure 7). For serotypes 3 and 19A,
blocking of PSGL-1 by treatment with KPL1 antibody, increased
the viability of bacterial cells, confirming that PSGL-1 recognizes
pneumococcal CPS of types 3 and 19A inducing phagocytosis
(Figure 7). Similar results were obtained for the additional
serotypes included in PCV15 and for serotype 8 as inhibition of
PSGL-1 receptor on human neutrophils by KPL1 allowed greater
levels of viable bacteria of these serotypes, demonstrating that
this receptor is important for the phagocytosis of serotypes 22F,
33F and 8 (Figure 7). However, uptake of serotypes 11A and 24F
remained similar in the presence or absence of PSGL-1 (Figure 7)
suggesting that these two serotypes are not recognized by this
receptor which may explain the emergence of these two serotypes
causing IPD cases in the last years.
Virulence of Isolates of Serotypes
22Fand 33F in a Mouse Sepsis Model of
Infection
Infection assays using the isogenic transformants of M11 strain
expressing the CPS of type 22F (P244) or 33F (P017) confirmed
that the CPS of serotype 22F confers a higher invasive capacity
than the CPS of serotype 33F as in these two strains the genetic
background is the same and the only difference is the CPS
expressed (Figure 8). The M11 strain expressing 22F had a
higher ability to replicate in blood (Figure 8A) and lethality was
increased compared to M11 with CPS of type 33F (Figure 8B).
This finding is consistent with the epidemiological results
mentioned above showing that serotype 22F is more prevalent
than serotype 33F in IPD in Spain. When clinical isolates of
both serotypes were analyzed, we found that serotype 22F is very
lethal regardless of the origin of the strain, killing all the mice
within the first 30 h (Figure 8). However, in serotype 33F, the
replication in blood of the pediatric isolate was markedly higher
compared to the adult isolate (Figure 8A) showing a marked
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FIGURE 4 | Analysis of biofilm formation of pediatric and adult clinical isolates. (A) Represents the comparison between adult and pediatric clinical isolates from four
different origins: 22F (left) and 33F (right). (B) Represents the comparison between 8 additional adult and pediatric clinical isolates from blood: 22F (left) and 33F
(right). M11, non-encapsulated strain; P244, 22F isogenic transformant; P017, 33F isogenic transformant. Black bars represent growth and white or color bars
represent biofilm formation. All data were normalized to the A595 CV blanks. Error bars represent standard deviations, and asterisks mark results that are statistically
significant (two-tailed Student’s t-test: ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001).
lethality (Figure 8C) which explains the higher resistance to the
phagocytosis of this strain in the planktonic cultures (Figure 6A).
DISCUSSION
The effectiveness of current pneumococcal conjugate vaccines
against targeted serotypes has been very successful decreasing
the burden of disease caused by these serotypes, although
unfortunately some countries have reported an increase of IPD
cases by certain non-vaccine types in recent years (Feikin et al.,
2013; Savulescu et al., 2017; Ladhani et al., 2018; Lewnard and
Hanage, 2019). This is the case for serotypes 22F and 33F with
different countries reporting increased rates in children and
adults after PCV13 (Kaplan et al., 2013; Pichon et al., 2013;
Moore et al., 2015; Golden et al., 2016; Balsells et al., 2017;
Cui et al., 2017). Serotypes 22F and 33F are also important in
terms of quality adjusted life years (QALY) as they caused the
highest QALY loss among non-PCV13 serotypes in children (van
Hoek et al., 2012). In Spain, our data show an increase of IPD
cases for serotype 22F in children and adults and a moderate
increase for serotype 33F mainly in adults which is consistent
with the situation of other countries worldwide described above.
Interestingly, serotype 22F significantly increased not only in
adults up to 64 years old but also in adults≥65 years old between
2009 and the 2017–2018 period (IRR 1.82; 95% CI 1.18–2.78
and IRR 1.83; 95% CI 1.28–2.62, respectively), whereas serotype
33F only increased significantly in the population ≥65 years
(IRR 2.00; 95% CI 1.1–3.64). The higher trend to infect adults
regardless the age in the case of serotype 22F may explain
why this serotype is increasing at a higher proportion than
serotype 33F in other countries (Golden et al., 2016; Ladhani
et al., 2018). The clonal spread of pneumococcal population
allows the dissemination of hypervirulent clones and multidrug
resistant genotypes that may contribute to the expansion of
certain serotypes and genotypes (Brueggemann and Spratt, 2003;
Ardanuy et al., 2014; Aguinagalde et al., 2015; Azarian et al.,
2018). Our data demonstrate that genotype ST433 is the most
frequent cause of IPD among clinical isolates of serotype 22F
in Spain. This is consistent with results from other countries
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FIGURE 5 | Influence of different CPS in the evasion of opsonophagocytosis.
(A) Bacterial survival of control strain M11 expressing different CPS and grown
as a planktonic culture. (B) Bacterial survival of control strain M11 expressing
different CPS and grown as a biofilm. Error bars represent standard
deviations, and asterisks mark results that are statistically significant
(two-tailed Student’s t-test: *P < 0.05; **P < 0.01; ***P < 0.001).
for this serotype causing IPD (Golden et al., 2016) although
it also has been found associated to nasopharyngeal carriage
(Sa-Leao et al., 2011). For serotype 33F, our results show up
to five different genotypes whereas isolates of this serotype
from other countries show a more clonal diversity with up
to eight different genotypes (Golden et al., 2018). In addition,
the majority of the clinical isolates of serotype 33F that are
circulating in Spain, belonged to the genotype ST717, which
is different to the situation in other countries such as Canada
where ST100 is the most frequent cause of IPD for serotype 33F
(Golden et al., 2016).
The use of isogenic transformants to make comparisons of
biofilm formation is very useful to avoid differences of each
clinical isolate (Domenech et al., 2014, 2015), since biofilm
formation is a multifactorial process (Domenech et al., 2013).
Hence, to analyze the influence of the CPS, the most reasonable
thing would be to use bacterial lines with the same genetic
background. Biofilm formation is a tool that can help to
predict the clinical impact and emergence of new serotypes that
colonize the nasopharynx after the introduction of new vaccines
FIGURE 6 | Evasion of opsonophagocytosis of 22F and 33F clinical isolates.
(A) Bacterial survival of clinical strains from pediatric (P) and adult (A) patients
and grown as a planktonic culture. (B) Bacterial survival of clinical strains from
pediatric (P) and adult (A) patients and grown as a biofilm. Error bars represent
standard deviations, and asterisks mark results that are statistically significant
(two-tailed Student’s t-test: ***P < 0.001).
(Domenech et al., 2014). These authors observed that serotype
19A was an excellent biofilm former with a marked capacity
of nasopharyngeal colonization (Domenech et al., 2014). This
ability to form thick biofilms can contribute to the pathogenesis
process of serotype 19A, explaining why is one of the most
predominant PCV13 serotypes in IPD (Domenech et al., 2014;
Fenoll et al., 2015; Ladhani et al., 2018). A similar approach
can be useful to explain the emergence of serotype 11A because
is also a good biofilm former and is associated to multidrug
resistance (Aguinagalde et al., 2015; Domenech et al., 2015).
Serotypes 8 and 3, despite forming little biofilm, remain two of
the most important serotypes in IPD, with serotype 8 being the
most predominant in Europe and the second in Spain, which
shows that biofilm formation is not the only factor to take into
account when determining the clinical impact of serotypes and
their future impact on the incidence of the disease. S. pneumoniae
isolates of serotypes 22F and 33F, which were found both in
carriage and causing IPD, and which are potentially highly
invasive (Yildirim et al., 2010), failed to produce substantial
amounts of biofilms in vitro. We observed the formation of
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FIGURE 7 | Phagocytosis mediated by PSGL-1 receptor. Results represent
bacterial survival of control strain M11 expressing different CPS and grown as
a planktonic culture. Phagocytic cells were incubated with an IgG isotype
negative control that does not block PSGL-1 (black bars), whereas cells
exposed to the KPL-1 antibody had the PSGL-1 blocked (hatched bars). Error
bars represent standard deviations, and asterisks mark results that are
statistically significant (two-tailed Student’s t-test: ***P < 0.001).
pneumococcal biofilm for clinical strains expressing capsules
of types 22F or 33F although in the majority of the cases
it was weak in agreement with previous observations using
isogenic transformants with CPS 22F and 33F (Domenech et al.,
2015). The biofilm levels of the control strain M11 in our
study are lower than those found in the study by Domenech
et al., mentioned above, but this aspect does not affect the
findings of the manuscript as we used the same M11 strain
to construct the isogenic mutants. The use of different brands
of multiwell plates, cristal violet, and a different multiplate
reader may have contributed to the variations of absorbance
values. In our study, the formation of biofilm does not explain
the increase in IPD by serotypes 22F and 33F, since being
bad biofilm formers, an expected phenotype that was already
described in previous work (Domenech et al., 2015), they
should not be very frequent in IPD. However, considering that
colonization of the nasopharynx is a multifactorial process and
that although the capsule is a prerequisite for the virulence of
the microorganism, there are numerous virulence factors that
also contribute to the pathogenesis of IPD and for serotypes 22F
and 33F may be playing a predominant role (Geno et al., 2015).
The CPS, determines the pneumococcal surface charge, and
this aspect influences colonization, because negatively charged
surfaces are associated with increased colonization (Weinberger
et al., 2009). Most pneumococcal capsules are anionic and most
pneumococcal clinical isolates have negative charge (Geno et al.,
2015; Morais et al., 2018). This anionic charge helps preventing
clearance by the mucus and helps repelling phagocytosis. There
are many examples of capsule-negative strains that colonize
the nasopharynx and also cause disease, such as serotype 19A,
which is a good biofilm former in vitro (Domenech et al.,
2014), colonizes efficiently the human nasopharynx (Adler et al.,
2019) and is one of the main PCV13 serotypes causing IPD.
In addition, anionic charge of the capsule does not seem to
be an impediment to colonize the upper respiratory tract and
produce IPD, but there are capsule-negative serotypes that are
good biofilm formers such as 35B and capsule-negative serotypes
that are bad biofilm formers such as 24F (Domenech et al.,
2015). This phenomenon would explain that serotype 22F is more
prevalent in the population, since due to the structure of its CPS
its net charge is negative whereas the CPS of 33F is neutral (Geno
et al., 2015). These differences in the CPS charge on 22F could
contribute to a better colonizing phenotype, and could explain
why there is a greater burden of disease due to serotype 22F
compared to 33F.
The heterogeneity in biofilm formation using clinical isolates
of this study is not surprising, since it confirms evidence
published before, where the genetic background and not only
the CPS modulate the adhesion of the pneumococcus and
formation of a biofilm on an artificial substrate (Moscoso et al.,
2006; Domenech et al., 2009, 2014). The novelty of this work,
resides in the differences found between pediatric biofilms and
adult biofilms, more precisely, the tendency of pediatric isolates
to form greater biofilms. These results are compatible with
the fact that the pediatric population is the largest carrier of
pneumococcus with up to 20–40% of asymptomatic colonization
in healthy children (Chaguza et al., 2019) suggesting that
pneumococcal isolates can modulate its ability to interact with the
nasopharyngeal epithelium by a mechanism related to increased
activation of intrinsic factors associated with biofilm formation.
The source of the strain (pediatric or adult) is certainly not
the only difference between the phenotype of the strains and
although the genotype did not contribute to our results, other
unrelated factors may be affecting.
Resolution of IPD is finely regulated by the efficient
recognition and clearance of S. pneumoniae by professional
phagocytes (Standish and Weiser, 2009; van der Poll and Opal,
2009). The pneumococcal CPS that surrounds the bacterium
and it is used to determine the serotype, is the most well-
established virulence factor, although the genetic background
also contributes significantly to the pathogenesis process (Hyams
et al., 2011; McAllister et al., 2011). Our study using strains
with the same genetic background but expressing different CPS,
demonstrates that the strain with capsule of type 3 was more
resistant to the phagocytosis process that the strain expressing the
capsule 19A. This is interesting because serotype 3 remains as one
of the most frequent causes of IPD in adults worldwide (Moore
et al., 2015; Ladhani et al., 2018). The higher resistant phenotype
conferred by the capsule of type 3 may be due to the higher
size and even abundance of the CPS expressed on these strains
(Choi et al., 2015). Among the two additional serotypes covered
by PCV15, the strain expressing the CPS of type 22F was more
resistant to the phagocytosis and much more virulent in a mouse
sepsis model than the strain of serotype 33F. This is consistent
with the epidemiological data presented in our study showing a
higher burden of disease caused by serotype 22F and may explain
why in other countries, serotype 22F is also more prevalent than
serotype 33F (Moore et al., 2015; Golden et al., 2016; Ladhani
et al., 2018). In bacteria growing as biofilms, strains expressing the
CPS of type 3, 11A and 24F were among the most resistant strains
to be phagocytosed. This is interesting as serotype 3 remains as
major cause of pneumonia in adults (Menéndez et al., 2017) and
Frontiers in Microbiology | www.frontiersin.org 12 February 2020 | Volume 11 | Article 309
fmicb-11-00309 February 25, 2020 Time: 19:22 # 13
Sempere et al. Impact of Pneumococcal Serotypes 22F and 33F
FIGURE 8 | Virulence of isolates of serotypes 22F and 33F in a sepsis model of infection. (A) Colony counts expressed as Log10 CFU/ml from the blood of mice
infected with M11 strain expressing serotype 22F (P244) or serotype 33F (P017) or with clinical isolates of serotypes 22F or 33F from pediatric origin (P) or adult
origin (A). (B) Survival curves of P244 vs. P017 strains. (C) Survival curves of clinical isolates of serotype 33F from pediatric origin (P) or adult (A). Error bars represent
standard deviations, and asterisks mark results that are statistically significant (two-tailed Student’s t-test: *P < 0.05; ***P < 0.001 for bacterial counts; and Log-rank
test *P < 0.05; **P < 0.01 for survival curves).
in patients with COPD, serotypes 3 and 11A are among the most
prevalent (Shoji et al., 2018). In addition, serotype 24F is more
prone to cause meningitis, showing an increase in clinical severity
(Balsells et al., 2018) which could be associated to the increase
resistant pattern to phagocytosis when replicating as a biofilm.
The repertoire of cellular receptors involved in the
phagocytosis of invading pathogens is critical for the outcome
of the infection. PSGL-1 on leukocytes plays a critical role in
host defense against pneumococcal infection. As a consequence
of pathogen-recognition by PSGL-1, pneumococcal strains are
efficiently phagocytosed and killed intracellularly, reducing
bacterial replication and dissemination in the host, contributing
therefore, to control the severity of the IPD process (Ramos-
Sevillano et al., 2016). Our results show that PSGL-1 receptor is
important for the phagocytosis of different serotypes including
the additional serotypes covered by PCV15. However, for
serotypes 11A and 24F, cells expressing PSGL-1 did not kill
efficiently these particular serotypes suggesting that strains
expressing these two CPS, may have an increased ability
to produce IPD. This is consistent with the emergence of
amoxicillin-resistant variants of serotype 11A with genotype
ST6521 that avoid efficiently the phagocytosis process and
are good biofilm formers (Aguinagalde et al., 2015) and with
the increased severity of infection by isolates of serotype 24F
(Balsells et al., 2018).
Overall, the results of this study may be of relevance to
understand critical aspects of the pathogenesis process such as
biofilm formation and interaction with phagocytes by prevalent
serotypes including the additional serotypes covered by the new
PCV15. Surveillance studies and characterization of emergent
pneumococcal strains remains necessary in order to explain what
features lead to the success of individual serotypes and genotypes.
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